Long-Term Antibody Response to SARS-CoV-2 in Children

Area of Science:

• Pediatric Immunology and Infectious Diseases
• Virology and Serology

Background:

• Long-term humoral immune responses to SARS-CoV-2 in children remain understudied, particularly with lagging pediatric vaccination rates.
• Understanding pediatric immune responses is crucial for managing COVID-19 and developing effective vaccination strategies.

Purpose of the Study:

• To prospectively investigate long-term humoral immune responses to SARS-CoV-2 in children.
• To compare pediatric and adult immune responses and analyze household transmission patterns.

Main Methods:

• Prospective cohort study (C19.CHILD Hamburg) screening children under 18 for SARS-CoV-2 via PCR.
• Antibody testing for 4657 participants, with follow-up serological testing of infected children and household contacts for 6 months.
• Comparison of serum IgG spike antibody concentrations between children and adults at various time points post-symptom onset.

Main Results:

• Identified 67 seropositive children (1.44%), with a median of 83 days post-symptom onset.
• Families with adult index cases showed higher seroprevalence than those with pediatric index cases (OR 1.79).
• Children demonstrated sustained seroconversion up to 9 months post-symptom onset, with antibody levels significantly higher than adults at 90, 180, and 270 days post-symptom onset.

Conclusions:

• Children exhibit distinct SARS-CoV-2 infection patterns, including higher antibody levels and prolonged immune responses compared to adults.
• Findings support the need for age-appropriate vaccination strategies and highlight potential differences in susceptibility to novel variants.
• Sustained pediatric humoral immunity underscores the importance of continued research into long-term COVID-19 outcomes in children.